Search

Relay Therapeutics Inc

Gesloten

SectorGezondheidszorg

19.73 -0.9

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

19.3

Max

19.95

Belangrijke statistieken

By Trading Economics

Inkomsten

-10M

-84M

Verkoop

-2.7M

350K

EPS

-0.41

Winstmarge

-23,916.286

Werknemers

202

EBITDA

-10M

-83M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+33.67% upside

Dividenden

By Acuity

Volgende Winsten

5 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

277M

4.4B

Vorige openingsprijs

20.63

Vorige sluitingsprijs

19.73

Nieuwssentiment

By Acuity

50%

50%

163 / 340 Rangschikking in Healthcare

Relay Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 aug 2026, 21:51 UTC

Social Media

Relay Therapeutics Inc is gaining in after-market trading, supported by social media discussions and a significant portfolio stake from Perceptive Advisors.

13 aug 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc is trading lower, reflecting broader declines in the biotechnology sector amid fluctuations and rising initial jobless claims.

10 aug 2026, 19:56 UTC

News
Social Media

Relay Therapeutics shares are higher after Citizens raised its price target to $26, citing confidence in the company's Phase 3 trials.

7 aug 2026, 20:06 UTC

News
Correlated Moves
Social Media

Barclays raised its price target on Relay Therapeutics to $30.00, contributing to positive sentiment amid ongoing analyst support following the company's Q2 earnings.

6 aug 2026, 23:02 UTC

News

Relay Therapeutics shares are lower in after-market hours following disappointing Q2 results, including a net loss of $83.7 million and revenue of $350,000.

5 aug 2026, 22:26 UTC

Relay Therapeutics Inc. shares advanced in after-market trading, maintaining a position above its 20-day moving average amid broader macroeconomic sentiment.

4 aug 2026, 19:26 UTC

Correlated Moves

Relay Therapeutics Inc is trading higher during Tuesday's session, continuing its upward trend since Monday's close. Broader market sentiment supports this performance.

3 aug 2026, 21:01 UTC

Relay Therapeutics Inc shares are lower in after-market trading, continuing a downward trend amid three consecutive sessions of declines and no specific news.

31 jul 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower in Friday's session, reflecting broader declines in the biotech sector amid rising yields and inflation concerns.

30 jul 2026, 17:36 UTC

Correlated Moves
News

Relay Therapeutics Inc is rising as it advances its PI3Kα inhibitor for breast cancer treatment, drawing renewed interest and nearing IPO levels.

29 jul 2026, 19:36 UTC

Macro Event

Relay Therapeutics Inc shares are higher Wednesday, supported by increased trading volume and recent Federal Reserve decisions on interest rates.

28 jul 2026, 18:06 UTC

Relay Therapeutics Inc. shares are lower today amid broader market declines, influenced by significant drops in Asian indices and concerns in the semiconductor sector.

27 jul 2026, 19:56 UTC

Relay Therapeutics Inc. is trading higher, reaching a peak earlier in the session, despite no specific news driving the increase.

22 jul 2026, 15:46 UTC

Correlated Moves

Relay Therapeutics shares are lower following first-quarter results, which showed a modest decline. The Russell 2000 Index's decrease may also be influencing performance.

21 jul 2026, 21:51 UTC

Relay Therapeutics Inc shares are higher in after-market trading, reflecting strong momentum amid renewed interest in technology stocks, particularly those related to AI.

20 jul 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc. is trading lower amid notable volatility, reflecting broader market declines alongside a drop in the ARK Genomic Revolution ETF.

Peer Vergelijking

Prijswijziging

Relay Therapeutics Inc Prognose

Koersdoel

By TipRanks

33.67% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 26.64 USD  33.67%

Hoogste 31 USD

Laagste 20 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Relay Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

12

Buy

0

Hold

0

Sell

Sentiment

By Acuity

163 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat